"Measure what can be measured and make measurable what is not so"
A medical technology company enabling precision and personalised medicine to become a reality in neuroscience research and development.
Our Missions
We transform any smartphone into a digital measurement laboratory for precision medicine development
Empowering patients to be the centre of gravity of neurological disease research
Pioneering the future of precision neurology
Indivi and RC2NB are dedicated to unlocking the immense potential of digital measurements in drug development.
Indivi’s close research cooperation with the teams at RC2NB (Co-CEOs Profs. Cristina Granziera and Ludwig Kappos) creates a unique intersection between expert knowledge in Software Development, Data Science, Clinical Science and Advanced Analytics (including Machine Learning and Artificial Intelligence).
The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) is an internationally renowned institution embedded in Basel University Hospital and University of Basel.
RC2NB specialises in the development and integration of innovative tools that comprehensively characterise the disease process, thus facilitating the development of better treatments and enabling personalised disease management for people affected by MS and other neuroimmune and neurodegenerative diseases.
Pioneering the future of precision neurology
Indivi and RC2NB are dedicated to unlocking the immense potential of digital measurements in drug development.
Indivi’s close research cooperation with the teams at RC2NB (Co-CEOs Profs. Cristina Granziera and Ludwig Kappos) creates a unique intersection between expert knowledge in Software Development, Data Science, Clinical Science and Advanced Analytics (including Machine Learning and Artificial Intelligence).
The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) is an internationally renowned institution embedded in Basel University Hospital and University of Basel.
RC2NB specialises in the development and integration of innovative tools that comprehensively characterise the disease process, thus facilitating the development of better treatments and enabling personalised disease management for people affected by MS and other neuroimmune and neurodegenerative diseases.
Pioneering the future of precision neurology
Indivi and RC2NB are dedicated to unlocking the immense potential of digital measurements in drug development.
Indivi’s close research cooperation with the teams at RC2NB (Co-CEOs Profs. Cristina Granziera and Ludwig Kappos) creates a unique intersection between expert knowledge in Software Development, Data Science, Clinical Science and Advanced Analytics (including Machine Learning and Artificial Intelligence).
The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) is an internationally renowned institution embedded in Basel University Hospital and University of Basel.
RC2NB specialises in the development and integration of innovative tools that comprehensively characterise the disease process, thus facilitating the development of better treatments and enabling personalised disease management for people affected by MS and other neuroimmune and neurodegenerative diseases.
Your partner in advancing precision endpoints to accelerate and derisk drug development in neurology
Indivi MS (dreaMSᴹᴰ)
Find out about how our Indivi MS (dreaMSᴹᴰ) medical device app can help you
Indivi MS (dreaMSᴹᴰ)
Find out about how our Indivi MS (dreaMSᴹᴰ) medical device app can help you
Indivi MS (dreaMSᴹᴰ)
Find out about how our Indivi MS (dreaMSᴹᴰ) medical device app can help you
For professionals
How Indivi aims at setting the new gold standard in neurological disorder assessment
For professionals
How Indivi aims at setting the new gold standard in neurological disorder assessment
For professionals
How Indivi aims at setting the new gold standard in neurological disorder assessment
Our technologies
Advancing digital endpoints to accelerate and derisk drug development in neuroscience
Our technologies
Advancing digital endpoints to accelerate and derisk drug development in neuroscience